As the Chief Executive Officer and Board Member of Alma Therapeutics, Yuval Amiri is at the forefront of revolutionizing drug delivery systems in the biotechnology industry. With a robust background in business development and a proven track record in identifying and executing new business opportunities,...
As the Chief Executive Officer and Board Member of Alma Therapeutics, Yuval Amiri is at the forefront of revolutionizing drug delivery systems in the biotechnology industry. With a robust background in business development and a proven track record in identifying and executing new business opportunities, Yuval is leading the charge in the development of the company’s next-generation oral biologics delivery platform. This innovative technology leverages a microneedle array approach, providing a needle-free alternative to traditional injectable drugs. By enhancing the oral delivery of biologics, Alma Therapeutics aims to significantly improve the quality of life for millions of patients who require chronic administration of injectable medications.
Under Yuval's leadership, Alma Therapeutics is not only advancing its proprietary technology but also forging strategic collaborations within the biotechnology sector. His expertise in biosimilars and pharmaceutical licensing has been instrumental in securing partnerships that drive innovation and expand market reach. Yuval's experience in fundraising and regulatory affairs further positions Alma Therapeutics to navigate the complexities of the pharmaceutical landscape, ensuring compliance while accelerating product development.
Yuval's commitment to start-up management and his role on the Board of Directors highlight his dedication to fostering a culture of collaboration and growth within the organization. By harnessing his extensive knowledge in pharmaceutical sales and pharmaceutics, he is steering Alma Therapeutics toward becoming a leader in the oral biologics space, ultimately transforming patient care and setting new standards in drug delivery technology.
